Hepatitis C Market Forecast 2032: FDA, EMA, PDMA Approvals, Epidemiology, Therapies, Clinical Trials and Companies by DelveInsight | BMS, Merck, Roche, Gilead Sciences, Johnson & Johnson, Abbvie
https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/26038163/hepatitis-c-market-forecast-2032-fda-ema-pdma-approvals-epidemiology-therapies-clinical-trials-and-companies-by-delveinsight-bms-merck-roche-gilead-sciences-johnson-johnson-abbvie/
$10 Billion Deal, page-12434
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.003(5.45%) |
Mkt cap ! $46.91M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.6¢ | 5.2¢ | $63.28K | 1.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12058 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 33995 | 1 |
View Market Depth
| Last trade - 15.51pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.2¢ |
Change
-0.003 ( 5.45 %) |
||||
| Open | High | Low | Volume | ||
| 5.4¢ | 5.5¢ | 5.2¢ | 64903 | ||
| Last updated 15.35pm 07/06/2024 ? | |||||
| BIT (ASX) Chart |